Florian Schlenk1, Peter Vajkoczy, Asita Sarrafzadeh. 1. Department of Neurosurgery, Charité Campus Virchow Medical Center, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Abstract
INTRODUCTION: Despite its clear association with impaired prognosis, it remains controversial whether hyperglycemia after aneurysmal subarachnoid hemorrhage (SAH) actively contributes to neuronal damage. This study aimed to identify a threshold for blood glucose predicting unfavorable outcome, and to evaluate differences in cerebral metabolism in normo and hyperglycemic SAH patients. METHODS: Prospectively, blood glucose and cerebral metabolism, measured by cerebral microdialysis, were evaluated in 178 patients (WFNS grade I-V; age 51.6 +/- 12.4 years) during days 1-7 after SAH. Patients were classified into groups with mean blood glucose levels <or=/> 6.1 mmol/l (110 mg/dl) and 7.8 mmol/l (140 mg/dl). Glasgow Outcome Score was assessed after 12 months. RESULTS: Higher inpatient blood glucose was associated with impaired prognosis, with a threshold of 7.5 mmol/l (135 mg/dl) distinguishing best between favorable and unfavorable outcome. Inpatient glucose levels >6.1 mmol/l (110 mg/dl) were associated with higher cerebral lactate and lactate/pyruvate ratio (P < 0.05). Cerebral glucose was elevated only at blood levels >7.8 mmol/l (140 mg/dl). Inpatient glucose levels above 7.8 mmol/l (140 mg/dl) were independent predictors of unfavorable outcome and mortality. CONCLUSION: Blood glucose levels >7.8 mmol/l (140 mg/dl), but not levels >6.1 mmol/l (110 mg/dl), independently predicted unfavorable outcome. While blood glucose levels >6.1 mmol/l (110 mg/dl) were already associated with slight metabolic derangements, cerebral glucose increased only at blood levels >7.8 mmol/l (140 mg/dl). Considering the risks associated with tight glycemic control, a moderate regimen accepting blood glucose levels up to 7.8 mmol/l (140 mg/dl) might be more reasonable after SAH.
INTRODUCTION: Despite its clear association with impaired prognosis, it remains controversial whether hyperglycemia after aneurysmal subarachnoid hemorrhage (SAH) actively contributes to neuronal damage. This study aimed to identify a threshold for blood glucose predicting unfavorable outcome, and to evaluate differences in cerebral metabolism in normo and hyperglycemic SAHpatients. METHODS: Prospectively, blood glucose and cerebral metabolism, measured by cerebral microdialysis, were evaluated in 178 patients (WFNS grade I-V; age 51.6 +/- 12.4 years) during days 1-7 after SAH. Patients were classified into groups with mean blood glucose levels <or=/> 6.1 mmol/l (110 mg/dl) and 7.8 mmol/l (140 mg/dl). Glasgow Outcome Score was assessed after 12 months. RESULTS: Higher inpatient blood glucose was associated with impaired prognosis, with a threshold of 7.5 mmol/l (135 mg/dl) distinguishing best between favorable and unfavorable outcome. Inpatient glucose levels >6.1 mmol/l (110 mg/dl) were associated with higher cerebral lactate and lactate/pyruvate ratio (P < 0.05). Cerebral glucose was elevated only at blood levels >7.8 mmol/l (140 mg/dl). Inpatient glucose levels above 7.8 mmol/l (140 mg/dl) were independent predictors of unfavorable outcome and mortality. CONCLUSION:Blood glucose levels >7.8 mmol/l (140 mg/dl), but not levels >6.1 mmol/l (110 mg/dl), independently predicted unfavorable outcome. While blood glucose levels >6.1 mmol/l (110 mg/dl) were already associated with slight metabolic derangements, cerebral glucose increased only at blood levels >7.8 mmol/l (140 mg/dl). Considering the risks associated with tight glycemic control, a moderate regimen accepting blood glucose levels up to 7.8 mmol/l (140 mg/dl) might be more reasonable after SAH.
Authors: Neeraj Badjatia; Mehmet A Topcuoglu; Ferdinando S Buonanno; Eric E Smith; Raul G Nogueira; Guy A Rordorf; Bob S Carter; Christopher S Ogilvy; Aneesh B Singhal Journal: Crit Care Med Date: 2005-07 Impact factor: 7.598
Authors: Paul Vespa; Robert Boonyaputthikul; David L McArthur; Chad Miller; Maria Etchepare; Marvin Bergsneider; Thomas Glenn; Neil Martin; David Hovda Journal: Crit Care Med Date: 2006-03 Impact factor: 7.598
Authors: Yaseen M Arabi; Ousama C Dabbagh; Hani M Tamim; Abdullah A Al-Shimemeri; Ziad A Memish; Samir H Haddad; Sofia J Syed; Hema R Giridhar; Asgar H Rishu; Mouhamad O Al-Daker; Salim H Kahoul; Riette J Britts; Maram H Sakkijha Journal: Crit Care Med Date: 2008-12 Impact factor: 7.598
Authors: Jennifer A Frontera; Andres Fernandez; J Michael Schmidt; Jan Claassen; Katja E Wartenberg; Neeraj Badjatia; Augusto Parra; E Sander Connolly; Stephan A Mayer Journal: Neurosurgery Date: 2008-01 Impact factor: 4.654
Authors: Pedro Diaz-Parejo; Nils Ståhl; Wangbin Xu; Peter Reinstrup; Urban Ungerstedt; Carl-Henrik Nordström Journal: Intensive Care Med Date: 2003-03-25 Impact factor: 17.440
Authors: Asita Sarrafzadeh; Daniel Haux; Ingeborg Küchler; Wolfgang R Lanksch; Andreas W Unterberg Journal: J Neurosurg Date: 2004-03 Impact factor: 5.115
Authors: P J Hutchinson; M T O'Connell; J Nortje; P Smith; P G Al-Rawi; A K Gupta; D K Menon; J D Pickard Journal: Physiol Meas Date: 2005-04-11 Impact factor: 2.833
Authors: Nyika D Kruyt; Geert Jan Biessels; J Hans DeVries; Merel J A Luitse; Marinus Vermeulen; Gabriel J E Rinkel; W Peter Vandertop; Yvo B Roos Journal: J Cereb Blood Flow Metab Date: 2010-07-14 Impact factor: 6.200
Authors: Raimund Helbok; J Michael Schmidt; Pedro Kurtz; Khalid A Hanafy; Luis Fernandez; R Morgan Stuart; Mary Presciutti; Noeleen D Ostapkovich; E Sander Connolly; Kiwon Lee; Neeraj Badjatia; Stephan A Mayer; Jan Claassen Journal: Neurocrit Care Date: 2010-06 Impact factor: 3.210
Authors: Andrew M Naidech; Kimberly Levasseur; Storm Liebling; Rajeev K Garg; Michael Shapiro; Michael L Ault; Sherif Afifi; H Hunt Batjer Journal: Neurocrit Care Date: 2010-04 Impact factor: 3.210
Authors: Freya M van Iersel; Arjen J C Slooter; Renee Vroegop; Annemiek E Wolters; Charlotte A M Tiemessen; Rik H J Rösken; Johannes G van der Hoeven; Linda M Peelen; Cornelia W E Hoedemaekers Journal: Intensive Care Med Date: 2012-08-21 Impact factor: 17.440
Authors: Haichen Wang; Michael L James; Talaignair N Venkatraman; Lawrence J Wilson; Polina Lyuboslavsky; Scott J Myers; Christopher D Lascola; Daniel T Laskowitz Journal: Neurocrit Care Date: 2014-02 Impact factor: 3.210
Authors: Andrew P Demidowich; Kristine Batty; Teresa Love; Sam Sokolinsky; Lisa Grubb; Catherine Miller; Larry Raymond; Jeanette Nazarian; M Shafeeq Ahmed; Leo Rotello; Mihail Zilbermint Journal: J Diabetes Sci Technol Date: 2021-02-20